Business Context and Reporting Period
Company: Pluristem Life Systems, Inc. (Nevada)
Filing Type: Form 8-K (Current Report)
Report Date: January 4, 2005 (Event Date); Signed March 23, 2005
Context: The company reported the issuance of a Notice of Allowance by the United States Patent Office for a fundamental invention related to its research and development, specifically a method for producing undifferentiated hematopoietic stem cells.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial performance.
Material Changes and Events
- Patent Allowance: Received Notice of Allowance for U.S. Patent Application No. 09/890,401 titled "Method of Producing Undifferentiated Hematopoietic Stem Cells Using a Stationary Phase Plug Flow Bioreactor."
- Executive Compensation: The Board approved a bonus for CEO Dr. Shai Meretzki consisting of:
- 2,400,000 shares of common stock.
- 2,400,000 common stock purchase warrants.
- Warrant Terms: Exercisable until November 30, 2006, at a price of $0.30 per share.
- Regulatory Basis: Securities issued in reliance on Regulation S.
Outlook, Risks, and Contingencies
- Management Commentary: Management considers the patent grant "extremely important" as it provides U.S. patent protection for a fundamental invention forming the basis of the company's R&D.
- Contingency: A fee payment is required by April 4, 2005, to finalize the patent grant.
- Registration: The company has agreed to register the shares issuable upon the exercise of the warrants.
Investor Verification Checklist
- Confirm the payment of the patent fee by the April 4, 2005 deadline to ensure the patent is officially granted.
- Verify the registration status of the 2,400,000 warrant shares.
- Assess the dilution impact of the 2,400,000 bonus shares and 2,400,000 warrants on existing shareholders.
- Review the commercial viability and timeline for the "Stationary Phase Plug Flow Bioreactor" technology.